NCT02485119 (Clinical Trial/ BAY94-9343)

Study Title
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks (Q3W) in Japanese Subjects With Advanced Malignancies (NCT02485119)

Trial Description
The primary objectives of the Phase I study 15404 are to evaluate the safety, tolerability and pharmacokinetics of BAY94-9343 given once every 3 weeks in Japanese subjects with advanced, refractory solid tumors. The secondary objectives are to investigate the efficacy, biomarkers and immunogenicity. This trial is sponsored by Bayer. [1]

Study Data

  • Condition: Neoplasms
  • Interventions:
    • Drugs used in this trial
      • BAY94-9343
  • Phase: I
  • Estimated Enrollment: 15
  • Start: August 2015
  • Estimated Completion: November 2017
  • Last verified: June 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: September 3, 2015
Information based on (NIH/NCI) and other sources.